Regulus Therapeutics (RGLS) USPTO patents

Utility

Compositions for treatment of polycystic kidney disease

6 Apr 23

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. Allerson

Filed: 25 Jul 22

Utility

Methods and Compositions for Treatment of Polycystic Kidney Disease

1 Dec 22

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH

Filed: 22 Jul 22

Utility

MicroRNA Compounds and Methods for Modulating MIR-10B Activity

31 Mar 22

Described herein are compositions and methods for the inhibition of miR-10b activity.

Charles R. Allerson

Filed: 12 Nov 19

Utility

Methods for Oral Delivery of Oligonucleotides

31 Mar 22

Provided herein are methods for oral administration of oligonucleotides.

Timothy Wright

Filed: 19 Jul 19

Utility

Methods for Treatment of Polycystic Kidney Disease

27 Jan 22

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

John R. ANDROSAVICH, B. Nelson CHAU, Vishal D. PATEL

Filed: 5 Oct 21

Utility

Methods for treatment of polycystic kidney disease

9 Nov 21

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

John R. Androsavich, B. Nelson Chau, Vishal D. Patel

Filed: 19 Mar 20

Utility

Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-Effect

10 Jun 21

Described herein are compositions and methods for the inhibition of miR-122 activity.

Charles R. Allerson, Steven S. Neben, Timothy Wright

Filed: 7 May 19

Utility

Modified Oligonucleotides for Treatment of Polycystic Kidney Disease

1 Apr 21

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. Allerson

Filed: 25 Sep 20

Utility

Compounds and methods for enhanced cellular uptake

9 Mar 21

Described herein are conjugated modified oligonucleotides that are complementary to a target RNA.

Balkrishen Bhat

Filed: 17 Jan 19

Utility

Methods for Treatment of Polycystic Kidney Disease

16 Dec 20

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH

Filed: 26 Aug 20

Utility

Methods and Compositions for Treatment of Polycystic Kidney Disease

16 Dec 20

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH

Filed: 26 Aug 20

Utility

Methods for Treatment of Polycystic Kidney Disease

22 Jul 20

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

John R. ANDROSAVICH, B. Nelson CHAU, Vishal D. PATEL

Filed: 18 Mar 20

Utility

Modified Oligonucleotides for Treatment of Polycystic Kidney Disease

27 May 20

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. Allerson

Filed: 3 Dec 17

Utility

Methods for treatment of polycystic kidney disease

27 Apr 20

Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

John R. Androsavich, B. Nelson Chau, Vishal D. Patel

Filed: 24 Aug 16

Utility

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

9 Mar 20

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs.

C. Frank Bennett, Susan M. Freier, Richard H. Griffey

Filed: 5 Sep 18

Utility

Methods for Treatment of Polycystic Kidney Disease

13 Nov 19

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH

Filed: 3 Dec 17

Utility

Compounds and Methods for Enhanced Cellular Uptake

9 Oct 19

Described herein are conjugated modified oligonucleotides that are complementary to a target RNA.

Balkrishen Bhat

Filed: 16 Jan 19